CompletedPhase 3

Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Canada250 participantsStarted 2006-04

Plain-language summary

Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the oral medication alitretinoin. The study aims to investigate the safety and efficacy of the medication when given over a period of 6 months.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Chronic hand dermatitis, rated as severe by physicians global assessment, present for at least 6 months, that has not responded to the avoidance of allergens and irritants and the use of topical steroids Exclusion Criteria: * female of childbearing potential, unless participating in a pregnancy prevention program * psoriasis * active major psychiatric condition

What they're measuring

Safety:

Adverse Events

Safety Laboratory

Radiological investigations (bone density, x-ray)

Trial details

NCT IDNCT00309621

SponsorBasilea Pharmaceutica

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-04

View on ClinicalTrials.gov More Hand Dermatoses trials